Malignant perivascular epithelioid cell tumor (PEComa) of uterus: A case report with literature review

Perivascular epithelioid cell tumor (PEComa) is a rare mesenchymal neoplasm involving various organs. Approximately 70 cases of gynecologic PEComas have been reported in the literature. Due to the paucity of cases, there is no definite treatment regimen established. We describe disease progression in a case of uterine PEComa with pulmonary metastasis in a 37-year-old woman who had been treated with surgery and various regimens of adjuvant treatment including vincristine, ifosfamide, cisplatin, sirolimus, doxorubicin, olaratumab, pazopanib and dacarbazine. Adequate management and prognosis still seem inconclusive and further case reports with randomized trials are needed to delineate the nature of this neoplasm.

Perivascular epithelioid cell tumor (PEComa); Uterus; Adjuvant chemotherapy; Vincristine; Sirolimus; Dacarbazine

[1] Agaimy A., Wunsch P.H.: ”Perivascular epithelioid cell sarcoma (malignant PEComa) of the ileum”. Pathol. Res. Pract., 2006, 202, 37.

[2] Zamboni G., Pea M., Martignoni G., Zancanaro C., Faccioli G., Gilioli E., et al.: ”Clear cell ”sugar” tumor of the pancreas. A novel member of the family of lesions characterized by the presence of perivascular epithelioid cells”. Am. J. Surg. Pathol., 1996, 20, 722.

[3] Folpe A.L., Kwiatkowski D.J.: ”Perivascular epithelioid cell neoplasms: pathology and pathogenesis”. Hum Pathol, 2010, 41, 1.

[4] Zekry N., Rettenmaier M.A., Abaid L.N., John C.R., Micha J.P., Brown J.V., 3rd, et al.: ”Perivascular epithelioid cell neoplasms: a systematic review of prognostic factors”. J. Minim. Invasive Gynecol., 2009, 16, 527.

[5] Hornick J.L., Fletcher C.D.: ”PEComa: what do we know so far?”. Histopathology, 2006, 48, 75.

[6] Harris G.C., McCulloch T.A., Perks G., Fisher C.: ”Malignant perivascular epithelioid cell tumour (”PEComa”) of soft tissue: a unique case”. Am. J. Surg. Pathol., 2004, 28, 1655.

[7] Insabato L., De Rosa G., Terracciano L.M., Fazioli F., Di Santo F., Rosai J.: ”Primary monotypic epithelioid angiomyolipoma of bone”. Histopathology, 2002, 40, 286.

[8] Folpe A.L., Mentzel T., Lehr H.A., Fisher C., Balzer B.L., Weiss S.W.: ”Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature”. Am. J. Surg. Pathol., 2005, 29, 1558.

[9] Fadare O.: ”Perivascular epithelioid cell tumor (PEComa) of the uterus: an outcome-based clinicopathologic analysis of 41 reported cases”. Adv. Anat. Pathol., 2008, 15, 63.

[10] Fadare O.: ”Uterine PEComa: appraisal of a controversial and increasingly reported mesenchymal neoplasm”. Int. Semin. Surg. Oncol., 2008, 5, 7.

[11] Stone J.L., Batty T., Nicklin J.: ”Cervical perivascular epithelioid cell tumour (PEComa) of the uterine cervix: cytological findings in a cervical smear”. Cytopathology, 2013, 24, 272.

[12] Azad N.S., Aziz A.B., Pervez S., Kayani N.: ”Uterine perivascular epithelioid cell tumour presenting as a cervical mass”. J. Pak. Med. Assoc., 2006, 56, 83.

[13] Jeon I.S., Lee S.M.: ”Multimodal treatment using surgery, radiotherapy, and chemotherapy in a patient with a perivascular epithelioid cell tumor of the uterus”. J. Pediatr. Hematol. Oncol., 2005, 27, 681.

[14] Liu J.L., Lin Y.M., Lin M.C., Yeh K.T., Hsu J.C., Chin C.J.: ”Perivascular epithelioid cell tumor (PEComa) of the uterus with aggressive behavior at presentation”. Hematol. Oncol. Stem. Cell Ther., 2009, 2, 426.

[15] Martignoni G., Pea M., Reghellin D., Zamboni G., Bonetti F.: ”PEComas: the past, the present and the future”. Virchows Arch., 2008, 452, 119.

[16] Vang R., Kempson R.L.: ”Perivascular epithelioid cell tumor (’PEComa’) of the uterus: a subset of HMB-45-positive epithelioid mesenchymal neoplasms with an uncertain relationship to pure smooth muscle tumors”. Am. J. Surg. Pathol., 2002, 26, 1.

[17] Dickson M.A., Schwartz G.K., Antonescu C.R., Kwiatkowski D.J., Malinowska I.A.: ”Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates”. Int. J. Cancer, 2013, 132, 1711.

[18] Italiano A., Delcambre C., Hostein I., Cazeau A.L., Marty M., Avril A., et al.: ”Treatment with the mTOR inhibitor temsirolimus in pa- tients with malignant PEComa”. Ann. Oncol., 2010, 21, 1135.

[19] Wagner A.J., Malinowska-Kolodziej I., Morgan J.A., Qin W., Fletcher C.D., Vena N., et al.: ”Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors”. J. Clin. Oncol., 2010, 28, 835.

[20] Bunch K., Sunde J.: ”Fertility sparing treatment of a malignant uter- ine perivascular epithelioid cell tumor: A case report”. Gynecol. On- col. Case Rep., 2014, 8, 14.

[21] Benson C., Vitfell-Rasmussen J., Maruzzo M., Fisher C., Tunariu N., Mitchell S., et al.: ”A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience”. Anticancer Res., 2014, 34, 3663.

[22] Gennatas C., Michalaki V., Kairi P.V., Kondi-Paphiti A., Voros D.: ”Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor”. World J. Surg. Oncol., 2012, 10, 181.

[23] Napolioni V., Moavero R., Curatolo P.: ”Recent advances in neu- robiology of Tuberous Sclerosis Complex”. Brain. Dev., 2009, 31, 104.

[24] Kenerson H., Folpe A.L., Takayama T.K., Yeung R.S.: ”Activa- tion of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms”. Hum. Pathol., 2007, 38, 1361.